|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for LY86 |
 Gene summary |
| Basic gene Info. | Gene symbol | LY86 |
| Gene name | lymphocyte antigen 86 | |
| Synonyms | MD-1|MD1|MMD-1|dJ80N2.1 | |
| Cytomap | UCSC genome browser: 6p25.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004271.3, | |
| Description | MD-1, RP105-associatedly-86protein MD-1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605241 | |
| HGNC : HGNC | ||
| HPRD : 05578 | ||
| Protein | UniProt: O95711 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_LY86 | |
| BioGPS: 9450 | ||
| Pathway | NCI Pathway Interaction Database: LY86 | |
| KEGG: LY86 | ||
| REACTOME: LY86 | ||
| Pathway Commons: LY86 | ||
| Context | iHOP: LY86 | |
| ligand binding site mutation search in PubMed: LY86 | ||
| UCL Cancer Institute: LY86 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for LY86 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | D84 | D84G | COAD | 1 | E103 | E103G | COAD | 1 | P100 | P100S | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for LY86 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | P100 | P100S | -1.3681175 | E103 | E103G | -0.87302924 | D84 | D84G | -0.77368845 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for LY86 from PDB |
| Top |
| Differential gene expression and gene-gene network for LY86 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for LY86 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0270611 | Brain Injuries | 1 | Biomarker |
| umls:C0006663 | Calcinosis | 1 | Biomarker |
| umls:C0018824 | Heart Valve Diseases | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for LY86 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of LY86 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | MAN | ALPHA-D-MANNOSE | 3b2d | C | D84 | MAN | ALPHA-D-MANNOSE | 3b2d | D | D84 | MAN | ALPHA-D-MANNOSE | 3b2d | C | P100 E103 | MAN | ALPHA-D-MANNOSE | 3b2d | D | P100 E103 |
| Top |
| Conservation information for LBS of LY86 |
| Multiple alignments for O95711 in multiple species |
| LBS | AA sequence | # species | Species | D84 | KELFLDLALMS | 1 | Homo sapiens | D84 | KELYAKVDLII | 1 | Gallus gallus | D84 | RKLFLDITLMA | 1 | Mus musculus | E103 | SYPICEAALPK | 1 | Homo sapiens | E103 | SETLCGPGLSK | 1 | Gallus gallus | E103 | SYPLCEEDQPK | 1 | Mus musculus | F82 | DIKELFLDLAL | 1 | Homo sapiens | F82 | SIKELYAKVDL | 1 | Gallus gallus | F82 | DIRKLFLDITL | 1 | Mus musculus | P100 | LNFSYPICEAA | 1 | Homo sapiens | P100 | LSYSETLCGPG | 1 | Gallus gallus | P100 | LNYSYPLCEED | 1 | Mus musculus | R149 | LYTEKRSTVAC | 1 | Homo sapiens | R149 | LTNEDRATVAC | 1 | Gallus gallus | R149 | LYNENRATVAC | 1 | Mus musculus | S98 | SVLNFSYPICE | 1 | Homo sapiens | S98 | TVLSYSETLCG | 1 | Gallus gallus | S98 | SILNYSYPLCE | 1 | Mus musculus | Y145 | VLLELYTEKRS | 1 | Homo sapiens | Y145 | ITARLTNEDRA | 1 | Gallus gallus | Y145 | LLLELYNENRA | 1 | Mus musculus | Y99 | VLNFSYPICEA | 1 | Homo sapiens | Y99 | VLSYSETLCGP | 1 | Gallus gallus | Y99 | ILNYSYPLCEE | 1 | Mus musculus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |